Neuro Hero Competitors

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

Lumosity is a leading brain training program, brought to you by Lumos Labs, Inc. Lumosity’s web and mobile games are designed by scientists to challenge core cognitive abilities. Lumosity’s scientists take neuropsychological and cognitive research tasks, or design new ones, and work with game designers to transform them into 50+ cognitive games. Designed to be both fun and adaptively challenging, Lumosity’s training program is accessible to people of all ages — helping them stay challenged to the full extent of their abilities. Lumos Labs also has a collaborative research initiative, the Human Cognition Project, which currently partners with over 90 university collaborators. Through the HCP, we grant qualified researchers free access to Lumosity’s cognitive training tasks, assessments, research tools, and, in some cases, limited access to data on cognitive task performance — helping them conduct larger, faster, and more efficient studies. For more information, please visit http://www.lumosity.com/hcp

Neurotrack is a cognitive care enablement platform that helps primary care teams detect, diagnose, and manage cognitive decline earlier. Founded on decades of neuroscience research, Neurotrack replaces outdated paper-based screeners with a fast, reliable digital assessment that fits into routine visits or can be self-administered by patients at home, before an appointment, or anywhere care happens. The result: providers gain the confidence to act on cognitive concerns rather than refer and wait, and patients get answers years sooner. Earlier detection also carries direct economic value. Under CMS's V28 risk adjustment model, accurate dementia diagnosis and documentation protect appropriate reimbursement, while earlier intervention reduces the avoidable hospitalizations and emergency utilization that drive costs in undiagnosed populations. With seamless integration into leading EMRs, including Epic, Neurotrack partners with health systems, health plans, and value-based care organizations to close the gap between the first signs of cognitive decline and a documented diagnosis with a care plan behind it.